The GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity Era

The source, as retrieved

Abstract

While the world celebrates the apparent end of the obesity epidemic through glucagon-like peptide-1 receptor agonist (GLP-1RA) pharmacotherapy, a largely uncharacterised crisis is quietly taking shape: the _malnutrition of the medicated_. GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound), now constitute a pharmaceutical market valued at over USD 62 billion in 2025 and are consumed by tens of millions of individuals worldwide. Yet the clinical discourse remains almost entirely fixated on weight reduction endpoints, while the nutritional consequences of chronic caloric suppression, altered gastric emptying, and rapid lean-mass loss receive comparatively little systematic attention. This review addresses that gap through a structured synthesis of data drawn from landmark randomised controlled trials (STEP 1, SURMOUNT-1, SURMOUNT-5), large-scale observational databases encompassing more than 480,000 adults, expert consensus documents, and current clinical nutrition guidelines. We demonstrate that GLP-1RA therapy is associated with lean-mass loss constituting 26–40% of total weight lost, that newly diagnosed nutritional deficiencies affect up to 22% of users within twelve months, and that reported protein intake among GLP-1 users falls to approximately 54 grams per day – critically below muscle-preservation thresholds. Building on this evidence, we introduce two original analytical constructs: (1) the NUTRIENT DENSITY REQUIREMENT INDEX (NDRI), a quantitative framework that calculates the proportional increase in protein and micronutrient intake per kilocalorie that a GLP-1 user must achieve relative to a non-medicated person to maintain lean-mass homeostasis; and (2) the METABOLIC QUALITY INDEX (MQI), a novel composite metric that reframes weight-loss success in terms of the fat-to-lean-mass loss ratio rather than total kilograms lost. Together, these constructs provide clinicians, dietitians, and policy-makers with actionable tools for the first evidence-based _Nutritional Safety Protocol for GLP-1 Pharmacotherapy_. The protocol is proposed as a replicable clinical standard applicable across primary care, endocrinology, and bariatric medicine worldwide.

Where this record came from